Login to Your Account

'Myriad' Patent Issues at Stake as High Court Conferences

By Marie Powers
Staff Writer

Friday, November 30, 2012

At Friday's conference session, the Supreme Court will consider for the second time whether to grant cert to Association for Molecular Pathology v. Myriad Genetics Inc., a challenge to the Salt Lake City-based company's claims on the BRCA1 and BRCA2 genes used in diagnostics for breast and ovarian cancers. The court's decision on whether to hear the case is expected Monday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription